Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors

American Journal of Kidney Diseases

Volumn 38, Issue 6, 2001, Pages 1145-1157

  Komers, Radko ^a,b   Anderson, Sharon ^a,b   Epstein, Murray ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure (BP); Cyclooxygenase 2 (COX 2); Hypertension; Nonsteroidal anti inflammatory drugs (NSAIDs); Renal; Renal dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ADULT; AGED; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NONHUMAN; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; RENOVASCULAR HYPERTENSION; REVIEW;

EID: 0035722949     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.29203     Document Type: Article

References (74)

1. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
2. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss eTe cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
3. The eicosanoids and their biochemical mechanisms of action
4. Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells
5. Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS 10-encoded protein is a functional prostoglandin G/H synthase
6. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
7. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells
8. Localization of cyclooxygenase-1 and-2 in adult and fetal human kidney: Implication for renal function
9. Selective increase of cyclooxygenase-2 expression in a model of renal ablation
10. Regulation of cyclooxygenase expression in the kidney by dietary salt intake
11. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly
12. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Batter-like syndrome
13. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells
14. Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: Interaction with neuronal NOS
15. Cyclooxygenase-2 modulates afferent arteriolar responses to increases in pressure
16. Cyclooxygenase-2 mediates increased renal renin content by low-sodium diet
17. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension
18. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2
19. Renin expression in COX-2-knockout mice on normal or low-salt diets
20. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
21. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition
22. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension
23. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
24. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake
25. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion
26. Acute upregulation of COX-2 by renal artery stenosis
27. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro
28. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival
29. Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride
30. 2 release and cyclooxygenase-2 expression in a mouse macula densa cell line
31. Nitric oxide regulates renal cortical cyclooxygenase-2 expression
32. Mechanical stretch/relaxation of cultured rat mesangial cells induces protooncogenes and cyclooxygenase
33. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation
34. 2 and prostaglandin H synthase-2 in rats
35. Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa
36. The cell biology of fibroblast cyclooxygenase
37. Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by edrenal glucocorticoids and mineralocorticoids
38. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition
39. Analgesic nephropathy
40. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of common mechanism
41. Minimal change glomerulopathy associated with nonsteroidal anti-inflammatory drugs
42. Volume status as a determinant of the influence of renal PGE on renal function
43. Acute oliguric renal failure induced by indomethacin: Possible mechanism
44. Renal prostaglandins and the control of renal function in liver disease
45. A meta-analysis of the effects of non-steroidal anti-inflammatory drugs on blood pressure
46. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
47. Attenuation of hypertensive effect of propranolol and thiazide diuretics by indomethacin
48. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy
49. Non-steroidal antiinflammatory drugs and hypertension in the elderly: A community-based cross-sectional study
50. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence
51. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic
52. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes
53. Differential effect of selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs
54. Induction of sodium retention by a COX-2 inhibitor in volume depleted dogs: Comparison with other COX inhibitors
55. Natriuretic response to increased pressure is preserved with COX-2 inhibitors
56. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
57. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex
58. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
59. Effects of celecoxib and naproxen on renal function in the elderly
60. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial
61. Renal safety profile of rofecoxib, a specific inhibitor of COX-2 in controlled clinical trials
62. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor
63. Gastrointestinal toxicity with celecoxib vs non-steroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis
64. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
65. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults. A randomized, controlled trial
66. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers
67. A clinical trial comparing rofecoxib to celecoxib and acetaminophen in the treatment of osteoarthritis: Early efficacy results
68. Cyclooxygenase-2 specific inhibitors and cardiorenal function: A randomised controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients
69. Are selective COX-2 inhibitors nephrotoxic?
70. Acute renal failure associated with rofecoxib
71. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats
72. Cyclooxygenase-2 (COX-2) inhibition decreases proteinuria in a hypertensive diabetic model
73. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril
74. Long-term glucose infusion increases arterial pressure in dogs with cyclooxygenase-2 inhibition